Ashford Capital Management Inc. Trims Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Ashford Capital Management Inc. reduced its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 23.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 544,035 shares of the specialty pharmaceutical company's stock after selling 167,859 shares during the quarter. Supernus Pharmaceuticals makes up about 2.1% of Ashford Capital Management Inc.'s holdings, making the stock its 20th largest position. Ashford Capital Management Inc. owned about 0.99% of Supernus Pharmaceuticals worth $16,963,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Commonwealth Equity Services LLC grew its holdings in Supernus Pharmaceuticals by 3.6% during the second quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company's stock valued at $273,000 after purchasing an additional 350 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Supernus Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock worth $61,000 after acquiring an additional 352 shares during the last quarter. GAMMA Investing LLC raised its stake in Supernus Pharmaceuticals by 97.1% in the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock valued at $25,000 after acquiring an additional 398 shares during the period. Louisiana State Employees Retirement System lifted its holdings in Supernus Pharmaceuticals by 2.2% during the second quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company's stock valued at $741,000 after purchasing an additional 600 shares during the last quarter. Finally, Assetmark Inc. boosted its position in Supernus Pharmaceuticals by 2.8% during the third quarter. Assetmark Inc. now owns 33,442 shares of the specialty pharmaceutical company's stock worth $1,043,000 after purchasing an additional 908 shares during the period.

Supernus Pharmaceuticals Stock Performance

SUPN traded up $0.06 on Tuesday, reaching $36.74. The company had a trading volume of 236,515 shares, compared to its average volume of 438,661. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $39.37. The business has a 50 day simple moving average of $34.95 and a 200 day simple moving average of $31.72. The company has a market cap of $2.03 billion, a price-to-earnings ratio of 34.28 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping analysts' consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The firm had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. During the same period in the previous year, the business posted ($0.29) EPS. The business's quarterly revenue was up 14.2% on a year-over-year basis. As a group, equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

Insider Activity at Supernus Pharmaceuticals

In other news, CEO Jack A. Khattar sold 125,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total value of $4,585,000.00. Following the sale, the chief executive officer now directly owns 926,172 shares in the company, valued at approximately $33,971,988.96. This trade represents a 11.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Frank Mottola sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total value of $554,700.00. Following the transaction, the senior vice president now owns 8,200 shares of the company's stock, valued at approximately $303,236. This represents a 64.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 154,213 shares of company stock worth $5,660,180 in the last three months. 9.30% of the stock is owned by insiders.

Analyst Ratings Changes

SUPN has been the topic of several recent analyst reports. Piper Sandler reiterated a "neutral" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cowen reiterated a "buy" rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.